NCT05861570

Brief Summary

This study was conducted to compare the efficacy of hydrodilatation with steroid with hyaluronic acid and steroid for treating adhesive capsulitis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
84

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 5, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 17, 2023

Completed
1 day until next milestone

Study Start

First participant enrolled

May 18, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 6, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 6, 2024

Completed
Last Updated

June 18, 2023

Status Verified

April 1, 2023

Enrollment Period

11 months

First QC Date

April 5, 2023

Last Update Submit

June 16, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • change in pain intensity

    pain intensity was measured by visual analog scale (0-10)

    0, 6, 12weeks

Secondary Outcomes (2)

  • change in Shoulder Pain And disability index

    0, 6, 12 weeks

  • change in glenohumeral joint range of motion

    0, 6, 12weeks

Study Arms (2)

hydrodilatation with steroid

EXPERIMENTAL

patient received ultrasound-guided 3cc NS + 40mg triamcinolone + 4cc xylocaine

Drug: normal salineDrug: lidocaine hydrochlorideDrug: Triamcinolone Acetonide

hydrodilatation with hyaluronic acid and steroid

ACTIVE COMPARATOR

patient received ultrasound-guided 3cc hyaluronic acid + 40mg triamcinolone + 4cc xylocaine

Drug: (Sodium Hyaluronate (Hyruan One , LG)Drug: lidocaine hydrochlorideDrug: Triamcinolone Acetonide

Interventions

Ultrasound guided injection using 3ml normal saline

hydrodilatation with steroid

Ultrasound guided injection using 3ml of Sodium Hyaluronate

hydrodilatation with hyaluronic acid and steroid

Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)

hydrodilatation with hyaluronic acid and steroidhydrodilatation with steroid

ultrasound guided steroid injection using 4ml of 40mg triamcinolone acetonide

hydrodilatation with hyaluronic acid and steroidhydrodilatation with steroid

Eligibility Criteria

Age35 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 35-65 years
  • onset of shoulder stiffness since over a month
  • limitation in the passive range of motion (ROM) over 30° when compared with the contralateral side in at least two of these three movements: forward flexion, abduction, or external rotation.

You may not qualify if:

  • ultrasound findings of rotator cuff tears,
  • plain radiography findings of significant glenohumeral joint arthritis,
  • accompanying cervical radiculopathy,
  • systemic inflammatory joint disease,
  • intraarticular injection into the glenohumeral joint within the past 3 months
  • history of surgery on the affected shoulders,
  • regular use of systemic non-steroidal anti-inflammatory drugs or corticosteroids,
  • allergy to corticosteroid or lidocaine.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taipei Veterans General Hospital

Taipei, 11217, Taiwan

RECRUITING

MeSH Terms

Conditions

Bursitis

Interventions

Saline SolutionHyaluronic AcidLidocaineTriamcinolone Acetonide

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical PreparationsGlycosaminoglycansPolysaccharidesCarbohydratesAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesTriamcinolonePregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Double (Participant, Outcomes Assessor)
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 5, 2023

First Posted

May 17, 2023

Study Start

May 18, 2023

Primary Completion

April 6, 2024

Study Completion

April 6, 2024

Last Updated

June 18, 2023

Record last verified: 2023-04

Locations